MIP Technologies and FeF Chemicals sign Research and Development Agreement
Advertisement
MIP Technologies AB, a developer of molecular molecularly imprinted polymers for separations and drug discovery, announced that it has signed a research and development agreement with FeF Chemicals, a subsidiary of Novo Nordisk. During this program of work, MIP Technologies will develop for FeF a novel separation material with the potential for use in large scale protein purification. Under the terms of the Agreement, MIP Technologies will receive R&D funding including milestone payments, while FeF/Novo Nordisk will receive a license for manufacturing and use of the new material. MIP Technologies will retain the rights to use this new material in all fields with the exception of applications in diabetes.